ICI-204,448
ICI-204,448 is a chemical compound that acts as a selective antagonist of the leukotriene D4 (LTD4) receptor. It is primarily used in scientific research to study the role of leukotrienes in various physiological and pathological processes.
Chemical Properties[edit]
ICI-204,448 is a member of the class of compounds known as quinolines. It has a molecular formula of C_20H_19N_3O_2 and a molecular weight of 333.39 g/mol. The compound is characterized by its high affinity and selectivity for the LTD4 receptor, making it a valuable tool in pharmacological studies.
Mechanism of Action[edit]
ICI-204,448 functions by competitively inhibiting the binding of leukotriene D4 to its receptor. Leukotrienes are inflammatory mediators derived from arachidonic acid through the lipoxygenase pathway. By blocking the LTD4 receptor, ICI-204,448 can modulate inflammatory responses, particularly in conditions such as asthma and allergic rhinitis.
Applications in Research[edit]
ICI-204,448 is widely used in preclinical studies to investigate the role of leukotrienes in various diseases. It has been instrumental in elucidating the mechanisms underlying inflammatory responses and has potential therapeutic implications for conditions characterized by excessive leukotriene activity.
Asthma[edit]
In asthma research, ICI-204,448 has been used to demonstrate the contribution of leukotrienes to bronchoconstriction and airway hyperresponsiveness. Studies have shown that blocking the LTD4 receptor can reduce the severity of asthma symptoms, highlighting the potential for leukotriene receptor antagonists in asthma management.
Allergic Rhinitis[edit]
ICI-204,448 has also been employed in studies of allergic rhinitis, where leukotrienes play a significant role in mediating nasal congestion and other symptoms. By inhibiting the LTD4 receptor, ICI-204,448 helps to clarify the pathways involved in allergic responses and supports the development of targeted therapies.
Safety and Toxicology[edit]
As with any pharmacological agent, the safety profile of ICI-204,448 is an important consideration. Preclinical studies have assessed its toxicity and potential side effects, providing valuable data for its use in research settings. However, detailed safety information specific to ICI-204,448 is limited and requires further investigation.
Conclusion[edit]
ICI-204,448 is a potent and selective LTD4 receptor antagonist with significant applications in the study of inflammatory diseases. Its ability to block leukotriene-mediated responses makes it a valuable tool in both basic and applied research, contributing to our understanding of conditions such as asthma and allergic rhinitis.
See Also[edit]
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
